CytoSorbents Corporation, a leader in blood purification treatment for life-threatening conditions, has released its financial results for the first quarter of 2025, ending March 31. The company reported a product revenue of $8.7 million, reflecting a 3% decrease from $9.0 million in the first quarter of 2024. On a constant currency basis, product revenue remained flat. Gross margin decreased to 71% from 77% in the corresponding quarter of the previous year. However, the operating loss improved by 17% to $3.9 million, down from $4.7 million in Q1 2024, thanks to a 12% reduction in operating expenses. Additionally, the company received $1.7 million in cash proceeds from the sale of its 2023 and amended 2022 Net Operating Loss and R&D tax credits. In terms of business highlights, CytoSorbents completed a Shareholder Rights Offering, raising $6.8 million in net proceeds, and released $5.0 million of restricted cash, enhancing liquidity by a total of $11.8 million. The company also expanded its global presence by opening a regional sales subsidiary in Dubai, United Arab Emirates, and appointed Thomas Shannon as Vice President of Marketing for North America and Melanie Grossman, CPA, as Vice President and Corporate Controller.